AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres
Recruiting
- Conditions
- Severe Asthma
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06455462
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
Phase 2
Recruiting
- Conditions
- Moderate to Severe Crohn's Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT06450197
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06448754
- Locations
- 🇮🇹
Research Site, Verona, Italy
🇨🇳Research Site, Taipei, Taiwan
Real-World Treatment Study of Soliris (Eculizumab)
Completed
- Conditions
- Observational
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT06448715
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT06435273
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06432764
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06429761
- Locations
- 🇮🇳
Research Site, Varanasi, India
Fasenra Pediatric Japan Post-Marketing Study(PMS)
Recruiting
- Conditions
- Bronchial Asthma
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06427876
- Locations
- 🇯🇵
Research Site, Saitama, Japan
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT06422689
- Locations
- 🇺🇸
Research Site, Greenville, North Carolina, United States
MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT06422676
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath